Healthcare, Pharmaceuticals & Medical Devices
April 07, 2019
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases that cause chest symptoms leading to coughing, difficulty in breathing and wheezing. Asthma impacts a patient during the night time whereas COPD affects the patient during the day time. They can coexist in the same individual whereas the cause and treatment of both these symptoms are different. Asthma is caused majorly due to allergies whereas COPD is a result of smoking. Asthma leads to inflammation of lungs and COPD leads to destructive illness of lungs.
This report analyzes the worldwide market for asthma and chronic obstructive pulmonary disease (COPD) for the period 2010 to 2017. The major product segments in this market consist of bronchodilators, anti-inflammatories, and combination therapies. The report also describes the key influencing factors for the global asthma and COPD market. Market analysis and forecasts are provided for the period 2018 through 2015.
Definition, estimates & forecast of the global asthma and COPD market from 2018 to 2025
• Analysis of sub-segments for asthma and COPD market
• Analysis of the latest trends in the industry
• Acumen into the size and shape of the market growth
This research is specially designed to estimate and analyze the demand and performance of the global asthma and COPD market. The report covers all the major segments of asthma and COPD market and provides in-depth analysis, market revenue, and trend analysis by segments and statistically refined forecast for the segments covered. The in-depth research and high level analysis will allow asthma and COPD product manufacturers, service providers, marketing companies, research and development agencies to make informed decisions about asthma and COPD manufacturing, marketing, growth strategies and how best to gain competitive advantage.
The report presents detailed analysis and forecast for the global and China asthma and COPD market based on the following segmentation:
• Short Acting Bronchodilators
• Long Acting Bronchodilators
• Inhaled Corticosteroids
• Monoclonal Antibodies
In the next five years, the global asthma and COPD drug market is expected to grow slowly, primarily because of expiry of patents of leading drug brands and price erosion in the market. However, by 2017, few novel drugs are expected to enter the asthma and COPD market, which will drive future growth. The existing asthma and COPD market is mainly driven by increasing patient population. The other factors that will drive the market include long term use of asthma and COPD drugs, increase in disposable income and improved access to medical care facilities in emerging economies.
Competition in the asthma market is becoming intense due to the increased entry of combinational therapies, inhaled corticosteroids and beta-agonists. It is expected that Symbicort, Advair and Singulair would be the leading drugs of the global asthma and COPD market, while GlaxoSmithKline, AstraZeneca and Merck will continue to be the market leaders till the patents on their drugs expire in the coming years.
The restraints in the asthma and COPD drug market is the threat of generic products in the market since many patents are going to expire in the coming years and governments have restrictions on healthcare budgets. The patent expiry of Merck’s Singulair in 2012 and Advairs’ in 2016 will shift the manufacturers to generic drugs. The purchasers will have high bargaining power due to large competition in the market and cost consciousness is expected to remain one of the major constraints in the COPD and asthma drug market.
The opportunities in the asthma and COPD market is huge as many companies are focusing on contract manufacturing outsourcing (CMO) and large players have entered this market with new product development. Increase in awareness about the benefits of timely diagnosis for asthma and COPD and availability of healthcare equipment for the detection of asthma and COPD in rural areas will further boost the market and growth opportunities for market players.
In China, growth in urbanization and change in lifestyle has projected sharp increase in occurrence of asthma in the recent years. The occurrence of asthma symptoms is higher in urban areas as compared to rural areas. Air pollution and smoking are the most important factors which have led to the rapid increase in asthma and COPD patients in China.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are diseases that cause chest symptoms leading to coughing, difficulty in breathing and wheezing. Asthma impacts a patient during the night time whereas COPD affect during the day time. They can coexist in the same individual whereas the cause and treatment of both these symptoms are different. Asthma is caused majorly due to allergies whereas COPD is a result of smoking. Asthma leads to inflammation of lungs and COPD leads to destructive illness of lungs.
The report contains the global scenario of Asthma and COPD market discussing detailed overview and market figures. The research report analyses the industry growth rate, industry capacity, and industry structure. The report analyses the historical data and forecasts the Asthma and COPD market size, production forecasts along with key factors driving and restraining the market
This research is specially designed to estimate and analyze the demand, performance and size of “Asthma and COPD” Market in China and Global scenario. The research will provide in-depth analysis of value chain, product sales, trend analysis and demand by geography. The study will present a comprehensive assessment of the stakeholders’ strategies and winning imperatives for them.
Our report gives you the following advantages:
• Find revenue predictions to 2017 for the World and China Asthma and COPD market
• Discover revenue forecasts to 2017 for leading products, assessing market potentials
• Assess leading companies, and discover their revenue prospects in near future
• See revenue forecasts to 2017 for leading markets - US, Europe, Asia and China
• Review R&D for asthma and COPD, assessing potential
• Investigate competition and opportunities influencing the industry and market
• Growth drivers and restrain of the industry and market from 2012 onwards